Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
GENPREX stock logo
GNPX
GENPREX
$0.16
-6.1%
$0.24
$0.14
$3.97
$5.49M-0.533.47 million shs2.63 million shs
LianBio stock logo
LIAN
LianBio
$0.06
+11.2%
$0.18
$0.27
$4.99
$6.13M0.231.04 million shs9,099 shs
Nutra Pharma Corp. stock logo
NPHC
Nutra Pharma
$0.00
-50.0%
$0.00
$0.00
$0.00
$710K-0.22157,900 shs7.02 million shs
ULURU Inc. stock logo
ULUR
ULURU
$0.00
$0.10
$0.79
$5.35M-3.136,691 shsN/A
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
GENPREX stock logo
GNPX
GENPREX
+1.16%+21.49%-30.76%-50.79%-74.87%
LianBio stock logo
LIAN
LianBio
+11.18%-6.90%-0.53%-84.25%-83.26%
Nutra Pharma Corp. stock logo
NPHC
Nutra Pharma
0.00%-50.00%-50.00%0.00%0.00%
ULURU Inc. stock logo
ULUR
ULURU
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
GENPREX stock logo
GNPX
GENPREX
1.857 of 5 stars
0.03.00.04.73.80.00.6
LianBio stock logo
LIAN
LianBio
N/AN/AN/AN/AN/AN/AN/AN/A
Nutra Pharma Corp. stock logo
NPHC
Nutra Pharma
N/AN/AN/AN/AN/AN/AN/AN/A
ULURU Inc. stock logo
ULUR
ULURU
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
GENPREX stock logo
GNPX
GENPREX
0.00
N/AN/AN/A
LianBio stock logo
LIAN
LianBio
0.00
N/AN/AN/A
Nutra Pharma Corp. stock logo
NPHC
Nutra Pharma
0.00
N/AN/AN/A
ULURU Inc. stock logo
ULUR
ULURU
0.00
N/AN/AN/A
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
GENPREX stock logo
GNPX
GENPREX
N/AN/AN/AN/A$0.04 per shareN/A
LianBio stock logo
LIAN
LianBio
N/AN/AN/AN/A$2.71 per shareN/A
Nutra Pharma Corp. stock logo
NPHC
Nutra Pharma
N/AN/AN/AN/AN/AN/A
ULURU Inc. stock logo
ULUR
ULURU
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
GENPREX stock logo
GNPX
GENPREX
-$21.11MN/A0.00N/AN/AN/A-809.27%-386.95%11/11/2025 (Estimated)
LianBio stock logo
LIAN
LianBio
-$110.29M-$0.81N/AN/AN/AN/A-33.17%-30.19%N/A
Nutra Pharma Corp. stock logo
NPHC
Nutra Pharma
N/AN/A0.00N/AN/AN/AN/AN/A
ULURU Inc. stock logo
ULUR
ULURU
N/AN/A0.00N/AN/AN/AN/AN/AN/A

Latest NPHC, GNPX, LIAN, and ULUR Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2025Q2 2025
GENPREX stock logo
GNPX
GENPREX
-$0.71-$0.17+$0.54-$0.17N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
GENPREX stock logo
GNPX
GENPREX
N/AN/AN/AN/AN/A
LianBio stock logo
LIAN
LianBio
N/AN/AN/AN/AN/A
Nutra Pharma Corp. stock logo
NPHC
Nutra Pharma
N/AN/AN/AN/AN/A
ULURU Inc. stock logo
ULUR
ULURU
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
GENPREX stock logo
GNPX
GENPREX
N/A
0.84
0.84
LianBio stock logo
LIAN
LianBio
N/A
10.06
10.06
Nutra Pharma Corp. stock logo
NPHC
Nutra Pharma
N/AN/AN/A
ULURU Inc. stock logo
ULUR
ULURU
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
GENPREX stock logo
GNPX
GENPREX
14.05%
LianBio stock logo
LIAN
LianBio
74.85%
Nutra Pharma Corp. stock logo
NPHC
Nutra Pharma
N/A
ULURU Inc. stock logo
ULUR
ULURU
N/A

Insider Ownership

CompanyInsider Ownership
GENPREX stock logo
GNPX
GENPREX
0.44%
LianBio stock logo
LIAN
LianBio
7.59%
Nutra Pharma Corp. stock logo
NPHC
Nutra Pharma
61.50%
ULURU Inc. stock logo
ULUR
ULURU
1.10%
CompanyEmployeesShares OutstandingFree FloatOptionable
GENPREX stock logo
GNPX
GENPREX
2033.47 million33.32 millionNo Data
LianBio stock logo
LIAN
LianBio
110108.06 million99.86 millionNot Optionable
Nutra Pharma Corp. stock logo
NPHC
Nutra Pharma
47.10 billion2.73 billionNot Optionable
ULURU Inc. stock logo
ULUR
ULURU
230.57 million30.24 millionNot Optionable

Recent News About These Companies

Uluru Dialogue vow to renew recognition fight
YouTubers Find Out Uluru's Rules Are No Joke
Uluru 1Q Net Y192.00M Vs Net Y48.00M

New MarketBeat Followers Over Time

Media Sentiment Over Time

GENPREX stock logo

GENPREX NASDAQ:GNPX

$0.16 -0.01 (-6.12%)
Closing price 04:00 PM Eastern
Extended Trading
$0.16 0.00 (-1.22%)
As of 05:48 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Genprex, Inc., a clinical-stage gene therapy company, focuses on developing gene-based therapies for patients with cancer and diabetes in the United States. The company's lead product candidate is REQORSA (GPX-001), which is in preclinical trials to treat non-small cell lung cancer and small cell lung cancer; and GPX-002, which is in preclinical trials to treat type 1 and type 2 diabetes. Its product pipeline comprises Acclaim-1, which is in phase 2a clinical trial for the treatment of non-small cell lung cancer; Acclaim-2, which is in phase phase 1/2 clinical trial for the treatment of non-small cell lung cancer; and Acclaim-3, which is in phase 1/2 clinical trial for the treatment of small cell lung cancer. The company also develops ONC-001, REQORSA as a monotherapy, which is in phase 1 clinical trial to treat advance non-small cell lung cancer; and ONC-002, REQORSA with Tarceva, which is in phase 2 clinical trial to treat non-small cell lung cancer. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.

LianBio stock logo

LianBio NASDAQ:LIAN

$0.06 +0.01 (+11.18%)
As of 08/27/2025

LianBio, a biopharmaceutical company, engages in developing and commercializing medicines for cardiovascular, oncology, opthalmology, and inflammatory diseases in China and other Asian countries. The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with preserved ejection fraction; TP-03 for the treatment of Demodex blepharitis and meibomian gland disease; NBTXR3 for the treatment of head and neck squamous cell carcinoma, and solid tumor; Infigratinib for the treatment of second-line and first-line cholangiocarcinoma, and gastric cancers; BBP-398 for solid tumors; Omilancor and NX-13 for ulcerative colitis and Crohn's disease; LYR-210 for chronic rhinosinusitis; and Sisunatovir for respiratory syncytical virus. It has a partnership with Tarsus Pharmaceuticals, Inc. to develop and commercialize TP-03 for the treatment of Demodex blepharitis; and Nanobiotix S.A. to develop and commercialize NBTXR3, a radioenhancer designed to be injected directly into a malignant tumor prior to standard radiotherapy. The company was incorporated in 2019 and is headquartered in Princeton, New Jersey.

Nutra Pharma stock logo

Nutra Pharma OTCMKTS:NPHC

$0.0001 0.00 (-50.00%)
As of 09:39 AM Eastern

Nutra Pharma Corp., a biopharmaceutical company, acquires, licenses, and commercializes pharmaceutical products and technologies, and homeopathic and ethical drugs for the management of pain, neurological disorders, cancer, and autoimmune and infectious diseases primarily in the United States. The company offers Nyloxin and Nyloxin Extra Strength products, which are used as an oral spray for treating lower back pain, migraines, neck aches, shoulder pain, cramps, and neuropathic pain, as well as a topical gel for treating joint pain, and pain associated with arthritis and repetitive stress; Pet Pain-Away, a homeopathic, nonnarcotic, nonaddictive, and overthecounter pain reliever to treat chronic pain in companion animals; Luxury Feet, an over-the-counter pain reliever and antiinflammatory product to treat pain or discomfort due to high heels and stilettos; Nyloxin Military Strength for treating pain to the United States Military and Veteran's Administration; and Equine Pain-Away, an over-the-counter topical pain reliever to relieve pain in horses. It is also involved in developing RPI-78M to treat neurological diseases and autoimmune diseases, including multiple sclerosis, adrenomyeloneuropathy, amyotrophic lateral sclerosis, rheumatoid arthritis, and myasthenia gravis; RPI-MN to treat viral diseases comprising human immunodeficiency virus/AIDS and herpes, as well as for general anti-viral applications; RPI-78 for pain and arthritis; and RPI-70 for pain. The company was incorporated in 2000 and is based in Plantation, Florida.

ULURU stock logo

ULURU OTCMKTS:ULUR

ULURU Inc., a specialty medical technology company, researches, develops, and commercializes a range of wound care and muco-adhesive film products based on its patented Nanoflex and OraDisc technologies in the United States and internationally. The company provides Altrazeal, a transforming powder dressing that is used for the treatment of various wounds, such as partial thickness burns, donor sites, and surgical and traumatic wounds, as well as chronic wounds, including diabetic foot, venous leg, and pressure ulcers. Its products also include Aphthasol paste for the treatment of canker sores; OraDisc A for canker sores; and OraDisc B, which is used for the treatment and management of oral pain. ULURU Inc. was founded in 1987 and is based in Addison, Texas.